BCAB
Price:
$1.74
Market Cap:
$84.10M
BioAtla, Inc., a clinical stage biopharmaceutical company, develops specific and selective antibody-based therapeutics for the treatment of solid tumor cancer. Its lead product candidate is BA3011, a conditionally active biologic (CAB) antibody-drug conjugate (ADC) for soft tissue and bone sarcoma tumors, non-small cell lung cancer (NSCLC), and ovarian cancer. It also develops BA3021, a CAB ADC for multiple solid tumor types, including NSCLC, melanoma, and ovarian cancer; and BA3071, which is a CAB anti-cytotoxic T-lymphocyte-associated antigen 4 antibody for renal cell carcinoma, NSCLC, small cell lung cancer, hepatocellular carcinoma, melanoma, bladder cancer, gastric cancer, and cervical ...[Read more]
Industry
Biotechnology
IPO Date
2020-12-16
Stock Exchange
NASDAQ
Ticker
BCAB
According to BioAtla, Inc.’s latest financial reports and current stock price. The company's current PE Ratio is -0.80. This represents a change of -24.41% compared to the average of -1.06 of the last 4 quarters.
The mean historical PE Ratio of BioAtla, Inc. over the last ten years is -16.37. The current -0.80 PE Ratio has changed 388.70% with respect to the historical average. Over the past ten years (40 quarters), BCAB's PE Ratio was at its highest in in the September 2023 quarter at -0.61. The PE Ratio was at its lowest in in the December 2019 quarter at -123.01.
Average
-16.37
Median
-15.11
Minimum
-33.25
Maximum
-0.95
Discovering the peaks and valleys of BioAtla, Inc. PE Ratio, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.
Maximum Annual Increase = 43.90%
Maximum Annual PE Ratio = -0.95
Minimum Annual Increase = -76.87%
Minimum Annual PE Ratio = -33.25
Year | PE Ratio | Change |
---|---|---|
2023 | -0.95 | -68.79% |
2022 | -3.05 | -57.10% |
2021 | -7.11 | -76.87% |
2020 | -30.74 | -7.55% |
2019 | -33.25 | 43.90% |
The current PE Ratio of BioAtla, Inc. (BCAB) is greater than its 3-year, greater than its 5-year, and greater than its 10-year historical averages
3-year avg
-3.70
5-year avg
-15.02
10-year avg
-16.37
BioAtla, Inc.’s PE Ratio is greater than PMV Pharmaceuticals, Inc. (-1.58), greater than C4 Therapeutics, Inc. (-3.44), greater than Nautilus Biotechnology, Inc. (-4.59), greater than Century Therapeutics, Inc. (-0.91), less than Passage Bio, Inc. (-0.57), greater than Ikena Oncology, Inc. (-1.22), greater than Olema Pharmaceuticals, Inc. (-6.07), less than Aerovate Therapeutics, Inc. (-0.62), greater than Adagene Inc. (-2.86), greater than Acrivon Therapeutics, Inc. Common Stock (-4.23), greater than Rezolute, Inc. (-3.80), less than AN2 Therapeutics, Inc. (-0.47), greater than Gracell Biotechnologies Inc. (-12.26), greater than Theseus Pharmaceuticals, Inc. (-3.19), greater than Monte Rosa Therapeutics, Inc. (-3.11), greater than Design Therapeutics, Inc. (-5.23), greater than Erasca, Inc. (-3.94), greater than Foghorn Therapeutics Inc. (-4.49), greater than Shattuck Labs, Inc. (-2.08), greater than Kymera Therapeutics, Inc. (-21.01), greater than Nurix Therapeutics, Inc. (-8.82),
Company | PE Ratio | Market cap |
---|---|---|
-1.58 | $77.28M | |
-3.44 | $374.42M | |
-4.59 | $319.80M | |
-0.91 | $123.69M | |
-0.57 | $43.48M | |
-1.22 | $81.56M | |
-6.07 | $677.46M | |
-0.62 | $54.85M | |
-2.86 | $115.55M | |
-4.23 | $250.26M | |
-3.80 | $240.80M | |
-0.47 | $30.44M | |
-12.26 | $989.87M | |
-3.19 | $181.50M | |
-3.11 | $349.21M | |
-5.23 | $264.42M | |
-3.94 | $807.96M | |
-4.49 | $416.63M | |
-2.08 | $167.05M | |
-21.01 | $2.89B | |
-8.82 | $1.50B |
One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like BioAtla, Inc. using the financials and key metrics that matter to you in a single view.
The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:
Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.
Get your free trial here.
The easiest way to analyze a company like BioAtla, Inc. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.
Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.
Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.
What is the PE Ratio?
How can you use the PE Ratio?
What is BioAtla, Inc.'s PE Ratio?
How is the PE Ratio calculated for BioAtla, Inc. (BCAB)?
What is the highest PE Ratio for BioAtla, Inc. (BCAB)?
What is the 3-year average PE Ratio for BioAtla, Inc. (BCAB)?
What is the 5-year average PE Ratio for BioAtla, Inc. (BCAB)?
How does the current PE Ratio for BioAtla, Inc. (BCAB) compare to its historical average?